Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 9, 2000 - Issue 5
Submit an article Journal homepage
75
Views
32
CrossRef citations to date
0
Altmetric
Drug Evaluation

Evaluation of mitoxantrone for the treatment of multiple sclerosis

Kewal K Jain Jain PharmaBiotech, Bläsiring 7, CH-4057 Basel, Switzerland. [email protected]
Pages 1139-1149 | Published online: 24 Feb 2005

Bibliography

  • BANSIL S, COOK SD, ROWHOSKI-KOCHAN C: Multiple sclerosis: immune mechanisms and update in current therapies.Ann. Neurol (1995) 37:S87–5101.
  • ARNASON BG: Immunologic therapy of multiple sclerosis.Ann. Rev. Med. (1999) 50:291–302.
  • HOHLFELD R: Therapeutic strategies in multiple sclerosis. I. Immunotherapy.Philos. Trans. R. Soc. Lond. B. Biol. ScL (1999) 354:1697–1710.
  • DONOGHUE S, GREENLEES C: Drugs in developmentfor the treatment of multiple sclerosis: antigen non-specific therapies-an update.Exp. Opin. Invest. Drugs (2000) 9:167–171.
  • JAIN KK: Neuroprotection in CNS Disorders. JainPharmaBiotech Publications, Basel, Switzerland, (2000).
  • WATSON CM, DAVISON AN, BAKER Det al: Suppressionof demyelination by mitoxantrone.Int. J. Immunophar-macol (1991) 13:923–930.
  • FIDLER JM, DEJOY SQ, GIBBONS JJ: Selective immuno-modulation by an antineoplastic agent mitoxantrone. Suppression of B lymphocyte function.J. Immunol. (1986) 137:727–732.
  • FIDLER JM, DEJOY SQ, SMITH FRet al.: Selectiveimmunomodulation by the antineoplastic agent mitoxantrone. jImmunol. (1986) 136:2747–2754.
  • EHNINGER G, SCHULER U, PROKSCH Bet al: Pharma-cokinetics and metabolism of mitoxantrone. A review.PharmacokineL (1990) 18:365–380.
  • KAPPOS L, GOLD R, KUNSTLER Eet al.: Mitoxantrone inthe treatment of rapidly progressive MS: a pilot study with serial gadolinum (Gd)-enhanced MRI.Neurology (1990) 40:261 (Abstract 539P).
  • GONSETTE RE, DEMONTY L: Immunosuppression withmitoxantrone in multiple sclerosis: a pilot study for two years in 22 patients.Neurology (1990) 40:261 (Abstract 537P).
  • NOSEWORTHY JH, HOPKINS MB, VANDERVOORT MKetal.: An open trial evaluation of mitoxantrone in the treatment of progressive MS.Neurology (1993) 43:1401–1406.
  • MAUCH E, KORNHUMBER HH, KRAPF H: Treatment ofmultiple sclerosis with mitoxantrone.Eur. Arch. Psychiatry Clin. NeuroscL (1992) 242:96–102.
  • KRAPF H, MAUCH E, FETZER Uet al.: Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone.Neuroradiology (1995) 37:113–119.
  • CURSIEFEN S, FLACHENECKER P, RIECKMANN. Pet al.:Mitoxantrone (Novantron) in therapy of severe multiple sclerosis. A retrospective study of 15 patients (article in German).Nervenarzt (1999) 70:723–731.
  • BASTIANELLO S, POZZILLI C, D'ANDREA Fet al.: Acontrolled trial of nitoxantrone in multiple sclerosis: serial MRI evaluation at one year.Can. J. NeuroscL (1994) 21:266–270.
  • MILLEFIORINI E, GASPERINI C, POZZILLI Cet al.:Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome.J. Neurol. (1997) 244:153–159.
  • EDAN G, MILLER D, CLANET Met al.: Therapeutic effectof mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.J. Neurol. Neurosurg. Psychiatry (1997) 62:112–118.
  • HARTUNG HP, GONSETTE R, MIMS STUDY GROUP: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, randomized, observer-blind European Phase III multicenter study - clinical results.Multiple Sclerosis (1998) 4:325 (Abstract).
  • HARTUNG H, GONSETTE RE, MIMS STUDY GROUP: Mitoxantrone in progressive multiple sclerosis (MS): clinical results and three-year follow-up of the MIMS trial.Multiple Sclerosis (1999) 5 (Suppl.):S15 (Abstract 56).
  • KRAPF H, MORRISSEY SP, ZENKER O, et al.: Mitoxantronein progressive multiple sclerosis: MRI results of the European Phase III trial.Neurology (1999) 52 (Suppl. 2):A495 (Abstract).
  • GONSETTE RE: Mitoxantrone immunotherapy in multiple sclerosis.Multiple Sclerosis (1996) 1:329–332.
  • DE CASTRO S, CARTONI D, MILLEFIORININ Eet al.: Noninvasive assessment of mitoxantrone cardiotox-icity in relapsing remitting multiple sclerosis.J. Clin. Pharmacol. (1995) 35:627–632.
  • MAUCH E, EISENMANN S, HAHN Aeta].: Mitoxantrone in the treatment of patients with multiple sclerosis: a large single center experience. Poster presentation at ECTRIMS/ACTRIS (1999) Sept 15–18, Basel, Switzerland.
  • ANONYMOUS: Immunex Novantrone MS use is likely to be second-line FDC.Reports Pink Sheet (1999) 61(5022–23.
  • BROCHET B: Non-specific immunosuppression and multiple sclerosis (Article in French).Rev. Neurol. (Paris) (1998) 154:629–634.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.